Valuation: Center Laboratories, Inc.

Market Cap 29.38B 915M 802M 741M 684M 1.3B 87.57B 1.32B 8.9B 3.46B 42.85B 3.43B 3.36B 149B P/E 2024
-28.2x
P/E 2025 3.64x
Enterprise Value 33.42B 1.04B 912M 842M 778M 1.48B 99.61B 1.51B 10.13B 3.93B 48.75B 3.91B 3.82B 169B EV / Sales 2024
22.3x
EV / Sales 2025 23.1x
Free-Float
73.35%
Yield 2024
1.71%
Yield 2025 4.21%
1 day-0.38%
1 week+3.28%
Current month+3.15%
1 month+3.83%
3 months-4.26%
6 months-2.24%
Current year-5.41%
1 week 38.7
Extreme 38.7
40.55
1 month 36.8
Extreme 36.8
40.55
Current year 36.8
Extreme 36.8
51.4
1 year 33.1
Extreme 33.1
51.4
3 years 29.12
Extreme 29.1236
58.79
5 years 29.12
Extreme 29.1236
58.79
10 years 20.99
Extreme 20.9884
64.21
Manager TitleAgeSince
Chief Executive Officer - 03/08/1998
Director of Finance/CFO - 08/12/2022
Chief Tech/Sci/R&D Officer - 01/07/1983
Director TitleAgeSince
Chairman - 30/11/2022
Director/Board Member 61 14/06/2010
Director/Board Member - 14/06/2010
Change 5-day change 1-year change 3-year change Capi.($)
-0.38%+3.28%+12.96%-19.57% 915M
-1.60%+2.02%+56.34%+168.94% 1,084B
-1.44%+3.71%+69.07%+65.40% 634B
-0.75%+0.67%+33.18%+86.52% 447B
-0.40%-2.02%+28.69%+26.15% 330B
-8.98%-10.06%+26.19%+28.45% 295B
-0.81%-2.20%+28.34%+45.95% 285B
-0.77%-3.27%-27.51%-39.51% 218B
-0.03%+1.84%+23.90%+68.30% 199B
-0.40%+7.82%+22.29%+82.50% 169B
Average -1.54%+2.52%+27.35%+51.31% 366.08B
Weighted average by Cap. -1.69%+2.48%+40.29%+85.29%

Financials

2024 2025
Net sales 1.62B 50.37M 44.18M 40.78M 37.69M 71.44M 4.82B 72.87M 490M 191M 2.36B 189M 185M 8.19B 1.52B 47.2M 41.4M 38.22M 35.32M 66.95M 4.52B 68.29M 459M 179M 2.21B 177M 173M 7.68B
Net income -1.1B -34.36M -30.14M -27.82M -25.71M -48.73M -3.29B -49.71M -334M -130M -1.61B -129M -126M -5.59B 9.32B 290M 255M 235M 217M 412M 27.79B 420M 2.83B 1.1B 13.6B 1.09B 1.07B 47.21B
Net Debt 4.48B 139M 122M 113M 104M 198M 13.35B 202M 1.36B 528M 6.53B 524M 512M 22.69B 4.04B 126M 110M 102M 94.14M 178M 12.05B 182M 1.22B 476M 5.9B 472M 462M 20.46B
Logo Center Laboratories, Inc.
Center Laboratories Inc is a Taiwan-based company engaged in the development of pharmaceutical products. The Company's products mainly focus on internal liquids, including syrups, suspensions, liquids and other dosage forms. Pharmacological classifications include respiratory tract therapeutics such as cough suppressants, sputum expectorants, asthma medications, and runny nose relief, while antipyretic and analgesic medications and gastrointestinal medications are also in great demand, and a variety of internal liquids and lozenges for the treatment of central nervous system (CNS) such as epilepsy, dysphoria, dementia, and Parkinson's disease have already been introduced into the market. The Company is a specialized manufacturer of internal liquid.
Employees
-
Date Price Change Volume
08/07/26 NT$39.35 -0.38% 2,447,035
07/07/26 NT$39.50 -0.75% 2,544,596
06/07/26 NT$39.80 +0.38% 4,071,591
03/07/26 NT$39.65 +3.26% 8,219,167
02/07/26 NT$38.40 +0.79% 3,044,141
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. 4123 Stock